secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0000950170-24-040655
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara and TuHURA enter definitive merger; combined company to focus on immuno-oncology
--------------------------------------------------------------------------------

- TuHURA stockholders to own ~97.15% of combined company; Kintara stockholders ~2.85% (or 94.55%/5.45% after CVR shares).
- Combined company to trade as 'HURA' on Nasdaq; merger expected to close in Q3 2024.
- TuHURA plans Phase 3 trial for IFx-2.0 personalized cancer vaccine in 2H 2024 under FDA accelerated approval pathway.
- TuHURA has $31M subscribed financing of convertible notes to provide cash runway into late 2025.
- CVRs issued to Kintara stockholders; up to 53.9M shares if milestone on REM-001 study met by Dec 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024040655/0000950170-24-040655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024040655/ktra-20240402.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-040655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer